This is a news story, published by Yahoo Finance, that relates primarily to OptuneLua news.
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
NovoCure Stock Skyrocketed. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest best stocks news, stock news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
NovoCureThe Motley Fool
•Business
Business & Economics
69% Informative
Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday .
The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session.
A key highlight was the announcement of European CE Mark approval for OptuneLua in the treatment of metastatic non-small cell lung cancer ( NSCLC ).
VR Score
65
Informative language
67
Neutral language
10
Article tone
formal
Language
English
Language complexity
43
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
2
Affiliate links
no affiliate links
